Empowered with Meg Ryan: HelpMeSee Episode Highlights Solutions to Global Cataract Blindness Crisis, Airing Nationwide in April
JERSEY CITY, N.J., April 16, 2025 /PRNewswire/ — HelpMeSee, a global nonprofit committed to ending preventable cataract blindness, is honored to be featured... Read more.
Grown Alchemist Launches in US on Nordstrom.com
The plant-powered, biotech-boosted beauty brand expands its North American retail presence with luxury retailer Nordstrom NEW YORK, April 16, 2025 /PRNewswire/... Read more.
Pudu Robotics’ PUDU T300 Honored with Red Dot Award 2025 for Product Design
SHENZHEN, China, April 16, 2025 /PRNewswire/ — Pudu Robotics, a global leader in the service robotics industry, continues its impressive streak of awards with... Read more.
Altair Partners with Databricks to Accelerate Data-Driven Innovation
Collaboration will provide seamless connection between Altair® RapidMiner® and the Databricks Data Intelligence Platform, amplifying data science and machine learning... Read more.
MEXC Announces Official Listing of PAWS (PAWS)
VICTORIA, Seychelles, April 16, 2025 /PRNewswire/ — MEXC, a leading global cryptocurrency exchange, announced the listing of PAWS (PAWS) on April 16, 2025(UTC).... Read more.
CRITEO TO ANNOUNCE FIRST QUARTER 2025 FINANCIAL RESULTS ON MAY 2, 2025
NEW YORK, April 16, 2025 /PRNewswire/ — Criteo S.A. (NASDAQ: CRTO), the Commerce Media company, will announce its financial results for the first quarter ended... Read more.
Pismo names Vishal Dalal as CEO
Rodrigo Melato steps up as Chief Commercial Officer SÃO PAULO, April 16, 2025 /PRNewswire/ — Pismo has announced leadership changes to further strengthen... Read more.
Fully-integrated browser AI, Aria, is now available to millions of Opera Mini users
Opera Mini, with over 100M users, now offers AI integration in its browser Amidst high data costs in key regions in Africa, Opera Mini provides affordable access... Read more.
RedHill Biopharma’s Positive Opaganib Weight Loss & Diabetes Data Published: Signals Potential $100B Market Disruption
GLP-1 comparable efficacy: Opaganib’s positive results, newly published in the journal Diabetes, Metabolic Syndrome and Obesity, demonstrated weight loss and... Read more.
Q32 Bio Doses First Patients in Both Part A Open-Label Extension and Part B of SIGNAL-AA Phase 2a Trial Evaluating Bempikibart in Alopecia Areata
— SIGNAL-AA Part B topline data readout on-track for 1H’26 — WALTHAM, Mass., April 16, 2025 /PRNewswire/ — Q32 Bio Inc. (Nasdaq: QTTB)... Read more.